All patients
Age < 65y (younger) Age > 65y ECOG 0 ECOG 1 Gender, female Gender, male Hemoglobin concentration < 10g/dl hemoglobin concentration > 10g/dl metastasis (liver ) metastasis (lymph node ) metastasis (visceral) PD-L1 < 1% PD-L1 > 1% PDL1 < 25% PDL1 >25% smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
urothelial cancer (UC) - bladder cancer (BC), Immune checkpoint association vs. platinum derivate, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results DANUBE (DT vs C - all population), 2020 0.85 [0.71; 1.01]
DANUBE (DT vs C - PDL1>25%), 2020 0.74 [0.59; 0.93]
0.81 [0.70 ; 0.93 ] DANUBE (DT vs C - all population), 2020, DANUBE (DT vs C - PDL1>25%), 2020 2 0% 1,098 moderate not evaluable progression or deaths (PFS)detailed results DANUBE (DT vs C - all population), 2020 1.23 [0.88; 1.72]
DANUBE (DT vs C - PDL1>25%), 2020 1.02 [0.62; 1.68]
1.16 [0.88 ; 1.54 ] DANUBE (DT vs C - all population), 2020, DANUBE (DT vs C - PDL1>25%), 2020 2 0% 1,098 moderate not evaluable DORdetailed results DANUBE (DT vs C - all population), 2020 0.44 [0.25; 0.75]
DANUBE (DT vs C - PDL1>25%), 2020 0.38 [0.19; 0.75]
0.41 [0.27 ; 0.63 ] DANUBE (DT vs C - all population), 2020, DANUBE (DT vs C - PDL1>25%), 2020 2 0% 489 moderate not evaluable objective responses (ORR)detailed results DANUBE (DT vs C - all population), 2020 0.59 [0.43; 0.80]
DANUBE (DT vs C - PDL1>25%), 2020 0.94 [0.64; 1.39]
0.73 [0.46 ; 1.16 ] DANUBE (DT vs C - all population), 2020, DANUBE (DT vs C - PDL1>25%), 2020 2 71% 1,098 moderate not evaluable AE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 0.55 [0.40; 0.78]
0.55 [0.40 ; 0.78 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results DANUBE (DT vs C - all population), 2020 1.51 [1.02; 2.22]
1.51 [1.02 ; 2.22 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable SAE (any grade)detailed results DANUBE (DT vs C - all population), 2020 1.67 [1.23; 2.28]
1.67 [1.23 ; 2.28 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable STRAE (any grade)detailed results DANUBE (DT vs C - all population), 2020 1.57 [1.06; 2.32]
1.57 [1.06 ; 2.32 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable TRAE (any grade)detailed results DANUBE (DT vs C - all population), 2020 0.32 [0.20; 0.50]
0.32 [0.20 ; 0.50 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 0.25 [0.18; 0.35]
0.25 [0.18 ; 0.35 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable TRAE leading to death (grade 5)detailed results DANUBE (DT vs C - all population), 2020 1.85 [0.17; 20.46]
1.85 [0.17 ; 20.46 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable TRAE leading to discontinuation (any grade)detailed results DANUBE (DT vs C - all population), 2020 1.30 [0.83; 2.03]
1.30 [0.83 ; 2.03 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Abdominal pain TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53]
0.92 [0.02 ; 46.53 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 2.78 [0.29; 26.84]
2.78 [0.29 ; 26.84 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 7.44 [0.39; 141.31]
7.44 [0.39 ; 141.31 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Alopecia TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53]
0.92 [0.02 ; 46.53 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Anaemia TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 0.02 [0.01; 0.10]
0.02 [0.01 ; 0.10 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Arthralgia TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 5.56 [0.28; 111.52]
5.56 [0.28 ; 111.52 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Arthritis TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15]
1.84 [0.06 ; 55.15 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Asthenia TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 0.65 [0.20; 2.08]
0.65 [0.20 ; 2.08 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 0.46 [0.02; 13.75]
0.46 [0.02 ; 13.75 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Colitis TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 7.44 [0.39; 141.31]
7.44 [0.39 ; 141.31 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Constipation TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15]
1.84 [0.06 ; 55.15 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 0.69 [0.15; 3.10]
0.69 [0.15 ; 3.10 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Diabetes TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15]
1.84 [0.06 ; 55.15 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 1.67 [0.56; 5.05]
1.67 [0.56 ; 5.05 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53]
0.92 [0.02 ; 46.53 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Fatigue TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 0.68 [0.23; 2.00]
0.68 [0.23 ; 2.00 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 0.30 [0.03; 2.95]
0.30 [0.03 ; 2.95 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Gastritis TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15]
1.84 [0.06 ; 55.15 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53]
0.92 [0.02 ; 46.53 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15]
1.84 [0.06 ; 55.15 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Hypersensitivity TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 0.46 [0.02; 13.75]
0.46 [0.02 ; 13.75 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53]
0.92 [0.02 ; 46.53 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 5.56 [0.28; 111.52]
5.56 [0.28 ; 111.52 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 3.70 [0.17; 82.33]
3.70 [0.17 ; 82.33 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Increase AST TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 1.85 [0.34; 10.18]
1.85 [0.34 ; 10.18 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 2.78 [0.29; 26.84]
2.78 [0.29 ; 26.84 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 15.41 [2.03; 116.88]
15.41 [2.03 ; 116.88 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53]
0.92 [0.02 ; 46.53 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 0.04 [0.00; 0.63]
0.04 [0.00 ; 0.63 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53]
0.92 [0.02 ; 46.53 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Myositis TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53]
0.92 [0.02 ; 46.53 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Nausea TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 0.11 [0.01; 0.90]
0.11 [0.01 ; 0.90 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Nephritis TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15]
1.84 [0.06 ; 55.15 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results Out of scale DANUBE (DT vs C - all population), 2020 0.01 [0.00; 0.09]
0.01 [0.00 ; 0.09 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 3.70 [0.17; 82.33]
3.70 [0.17 ; 82.33 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Pancytopenia TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 0.11 [0.01; 2.16]
0.11 [0.01 ; 2.16 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15]
1.84 [0.06 ; 55.15 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Pruritic rash TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15]
1.84 [0.06 ; 55.15 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Pruritus TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 3.70 [0.17; 82.33]
3.70 [0.17 ; 82.33 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 0.92 [0.13; 6.57]
0.92 [0.13 ; 6.57 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Rash TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 7.44 [0.39; 141.31]
7.44 [0.39 ; 141.31 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Sepsis TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 0.46 [0.02; 13.75]
0.46 [0.02 ; 13.75 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Stevens-Johnson syndrome TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53]
0.92 [0.02 ; 46.53 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15]
1.84 [0.06 ; 55.15 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 0.02 [0.00; 0.29]
0.02 [0.00 ; 0.29 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15]
1.84 [0.06 ; 55.15 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable Vomiting TRAE (grade 3-4)detailed results DANUBE (DT vs C - all population), 2020 0.36 [0.07; 1.89]
0.36 [0.07 ; 1.89 ] DANUBE (DT vs C - all population), 2020 1 0% 653 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-30 23:24 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 11,288,153,157,290,155,154,289,188,189,239,158,252,253,76,238,236,237
- treatments: 856,634,861,416,864,769,980